Connect
MJA
MJA

Stroke prevention and stroke thrombolysis: quantifying the potential benefits of best practice therapies

Timothy J Kleinig, Thomas E Kimber and Philip D Thompson
Med J Aust 2009; 190 (12): 678-682.
Published online: 15 June 2009

Abstract

Objective: To identify and quantify current deficiencies in primary and secondary stroke prevention, as well as potential gains from optimal employment of thrombolysis.

Design, participants and setting: Observational study of 259 consecutive patients admitted to a tertiary hospital stroke unit from 24 January 2006 to 10 January 2007, with retrospective assessment of prestroke risk factors and therapies to determine stroke preventability, based on relative risk reductions from published meta-analyses of preventive therapies.

Main outcome measures: Numbers of strokes preventable by optimal risk factor modification and numbers of strokes with preventable disability through optimal thrombolysis; characteristics of patients with preventable strokes; contributions of each risk factor to stroke preventability.

Results: 183 patients had a disabling or fatal stroke; 135 patients had at least one suboptimally managed risk factor. On the basis of prespecified stroke preventability weightings, 70 strokes were preventable. The younger the patient, the more likely that the stroke was potentially preventable (relative risk [RR] for age < 60: ≥ 80 years, 3.10; 95% CI, 1.96–4.92). Smoking, inadequate control of hypertension and suboptimal anticoagulation accounted for nearly 90% of preventable strokes. Patients with target systolic blood pressures of 130 mmHg or lower were more likely to have inadequately controlled hypertension (RR, 4.27; 95% CI, 2.58–7.05). By comparison, disability could have been prevented in four strokes through optimal thrombolysis.

Conclusions: A significant proportion of stroke remains preventable, especially in younger patients, by optimal modification of risk factors, particularly smoking, blood pressure and anticoagulation. Only a small proportion of patients will benefit from best-practice thrombolysis.

Stroke is common, and frequently fatal or disabling.1,2 In Australia, stroke is the second leading contributor to disease burden after ischaemic heart disease.3

Stroke occurs most commonly in patients with known risk factors. It has been estimated that the proportion attributable to these factors is as high as 80%,4 implying that stroke is largely a preventable disease. However, as various preventive therapies are now widely employed, it is uncertain whether these estimates still apply.

The effects of ischaemic stroke (the most common kind) can potentially be minimised with thrombolysis.5 However, thrombolysis rates in Australia are around 3%,6 and treatment rates, even at centres of excellence, struggle to exceed 10%.7 There is therefore scope for reducing the effects of stroke by expanding thrombolysis.

We designed The Royal Adelaide stroke disability Prevention Study (TRAPS) to identify and quantify current deficient areas in primary and secondary prevention, as well as to estimate the potential benefits of optimal thrombolysis.

Methods

We performed an observational stroke unit-based study with retrospective assessment of prestroke therapies. Eligibility for thrombolysis was determined at or shortly after admission.

The Royal Adelaide Hospital serves a local population within metropolitan Adelaide, and is also a tertiary referral centre for adjacent rural areas. Its stroke unit admits all patients with a diagnosis of acute stroke regardless of age or severity, except those requiring neurosurgical intervention (subarachnoid haemorrhage and some with intracerebral haemorrhage) and those transferred from high-level residential care. The study was approved by the Royal Adelaide Hospital Research Ethics Committee.

Information was collected about all consecutive patients with a final diagnosis of stroke who were admitted to the stroke unit from 24 January 2006 to 10 January 2007, except those from whom informed consent could not be obtained. Information about prestroke health status and therapies was obtained from the treating general practitioner or specialist.

Assessment of stroke preventability

We calculated percentage stroke preventability using a previously published method,8 assuming a multiplicative scale for relative risk reductions of underutilised therapies:

RRR = (1  [RR1 × RR2 × RR3 × RRn]) × 100

(where RRR represents relative risk reduction, and RRn represents the relative risk of stroke if therapyn had been employed).

Factors assessed included untreated or suboptimally treated hypertension,9 untreated or suboptimally treated atrial fibrillation,10 indications for statin11 or antiplatelet therapy but no treatment,12 inappropriate hormone replacement therapy,13 untreated “normal” post-stroke blood pressure,14 untreated symptomatic carotid disease,15 smoking,16 and subtherapeutic warfarinisation,17 (Box 1). Only risk factors with strong data from randomised controlled trial (RCT) meta-analyses or large RCTs were included, except for smoking,16 which has robust population relative risk data, and for suboptimal anticoagulation, which cannot feasibly be assessed in an RCT but clearly increases stroke risk.17,18 Studies on the effect of smoking and hypertension on stroke risk have not always reliably distinguished ischaemic and haemorrhagic stroke, and hence the impact of these factors on the preventability of ischaemic and haemorrhagic stroke was not differentially weighted.

Efficacy of hypertension management was assessed by comparing the last two prestroke systolic blood pressure readings with national guidelines.19 Undertreated hypertension was identified where both readings were more than 10 mmHg above those recommended in guidelines, and grossly undertreated hypertension was identified where both were more than 20 mmHg above. Only systolic pressure was considered.20 Adequacy of anticoagulation for atrial fibrillation was assessed by comparison with national guidelines,21 and hypercholesterolaemia with Pharmaceutical Benefits Scheme guidelines applicable in 2006. Hormone replacement therapy was designated inappropriate unless a patient had significant menopausal symptoms refractory to other therapies. Inadequate warfarininsation was defined as subtherapeutic admission and preadmission international normalised ratio (INR) readings or, in the case of periprocedural stroke, a failure to follow national guidelines.22 All smoking-associated strokes were deemed potentially preventable.

If risk factor modification was considered inadequate, both the patient and treating doctor were asked if there were extenuating circumstances (such as medication side effects). If extenuating factors were identified, the stroke was deemed not preventable.

The total number of potentially preventable strokes was obtained by multiplying the total number of strokes by the average “stroke preventability”. The contribution of each risk factor to this total figure was also extracted.

Potential prevention of disability from stroke by thrombolysis was assessed by comparing actual versus potential thrombolysis cases (ie, patients with ischaemic stroke potentially able to reach hospital within 120 minutes of stroke onset with no contraindications). A number needed to treat (NNT) of 8 (95% CI, 5.3–15.3) was derived from a recent meta-analysis,5 being the number needed to render one patient who had had a stroke minimally symptomatic or asymptomatic (a modified Rankin score of ≤ 1).

Statistical analysis

Categorical variables potentially influencing stroke preventability were assessed by the χ2 test with two-tailed P values. Variables prospectively hypothesised to be associated with stroke preventability were being male, social isolation, rural address, non-English-speaking background and older age. A post-hoc analysis was conducted of the association between hypertension targets not being reached and whether those targets were standard (140/90 mmHg) or lower (130/85 mmHg or less). Relative risks and 95% CIs were calculated. Analyses were performed with GraphPad Prism, version 5.00 for Windows (GraphPad Software, San Diego, Calif, USA).

Results
Baseline data

During the study period, 306 patients were admitted to the stroke unit; 43 had a diagnosis other than stroke. Four patients did not or could not consent to inclusion in the study, leaving a total of 259 patients who had had a stroke.

Demographic data, risk factor prevalence and therapies, and stroke characteristics are shown in Box 2. Almost all patients identified a treating doctor. Stroke type and mortality, median ages and sex distribution did not differ from recent Australian population-based studies.2,23 Over 70% of patients were being treated with at least one preventive therapy. The most common previously identified risk factor was hypertension. Most patients with hypertension were being treated, many with polytherapy.

Risk factor modification

Overall, 135 patients (52%) had at least one suboptimally modified risk factor (Box 3), and 10% had two or more. In these patients, average stroke preventability was 52%. Therefore, overall, 70 out of 259 strokes (27%) were preventable.

Nearly 20% of patients were active smokers. Consistent with the assumptions listed in the methods, smoking was the single largest contributor to preventable stroke, contributing to nearly half the total.

At least two recent blood pressure measurements had been recorded for 95% of patients; a quarter were not within the target range. Patients were more likely to have had inadequately controlled hypertension if their target systolic pressure was 130 mmHg or less (patients with diabetes, young-onset hypertension and renal disease;19 relative risk, 4.27; 95% CI, 2.58–7.05; P < 0.001).

Of the 48 patients with ischaemic stroke in the setting of known atrial fibrillation, only 20 had received appropriate therapy. High-risk atrial fibrillation was treated with aspirin or nothing in 21 patients. The remaining seven patients were suboptimally anticoagulated. Warfarin was associated with intracerebral haemorrhage in three cases. Overall, smoking, inadequate blood pressure control and suboptimal use of warfarin accounted for nearly 90% of preventable strokes.

We had hypothesised that the very old were more likely to be treated suboptimally. However, as shown in Box 4, we found the opposite. There was a strong trend for the association of suboptimally managed risk factors with younger age, principally because of the prevalence of smoking and unmet blood pressure targets in this group. Our other hypotheses, that rural address, social isolation, non-English-speaking background and being male might be linked to stroke preventability, were not supported.

Potential for expanding thrombolysis

Compared with optimal modification of risk factors, fewer strokes were “preventable” with best-practice thrombolysis (Box 5). Roughly a quarter of stroke patients were ineligible for treatment with tissue plasminogen activator because of intracerebral haemorrhage, or were not transferred in time from rural hospitals. Of the remaining 168, 125 had a contraindication to thrombolysis, most commonly because of time-of-onset uncertainty (most often awaking with neurological symptoms) or unavoidable presentation outside the 3-hour window (eg, being found by relatives after a prolonged period). A third of potential thrombolysis (14/42) candidates received treatment. Assuming a number needed to treat of 8,5 disability could potentially have been prevented in four strokes under optimal conditions.

Discussion

Our study demonstrates the continued high prevalence of suboptimally modified risk factors in a hospital-based cohort of consecutive patients admitted with stroke from 24 January 2006 to 10 January 2007 from whom informed consent could be obtained. Although this was a highly treated population (over 70% were being treated with at least one preventative therapy), over half had at least one suboptimally modified risk factor. According to the assumptions outlined in our methods, over a quarter of strokes were preventable. By comparison, best-practice thrombolysis could have prevented disability in a smaller number of strokes.

Estimates of stroke preventability were conservative, as lifestyle factors contributing independently to stroke risk that cannot be readily quantified were not included (eg, obesity,24 physical inactivity,25 alcohol consumption26 and poor diet24). Furthermore, statin therapy,27 therapeutic anticoagulation18 and angiotensin-converting enzyme inhibition28 not only prevent stroke, but also lessen stroke severity.

Stroke preventability is difficult to define and quantify, and our finding that a quarter of strokes could be prevented is less than the 80% attributable risk cited in the introduction,4 and a recently estimated 80% reduction in recurrence risk with best-practice treatments.8 However, our population was already being treated with a number of preventive therapies, in contrast to patients in both cited articles, in which no therapy, rather than some therapy was assumed. Additionally, one article focused only on secondary prevention, and included dietary and exercise interventions,8 which are not proven on a population basis for primary stroke prevention. Our study identifies and quantifies the risk factors that remain suboptimally managed in an era of widespread medical therapies and declining smoking habits.

We found that the three suboptimally modified risk factors with the greatest impact were smoking, hypertension and atrial fibrillation. This finding is consistent with a recent population-based study of general practice patients,29 and broadly consistent with international data.30 Smoking and suboptimally treated hypertension were more prevalent in younger patients, explaining the higher prevalence of “stroke preventability” in this group. These patients often also had lower blood pressure target values, which could only have been achieved by combination therapy. Hypertension and other risk factors were well managed in older patients, despite the greater prevalence of risk factors, refuting the possibility that therapeutic nihilism or undertreatment among older people may be a significant cause of ischaemic stroke. We did, however, demonstrate a continued reluctance of health practitioners to prescribe warfarin and of patients to take it, also documented elsewhere.31 It is to be hoped that new data confirming the efficacy and safety of warfarin therapy in older people will help allay persisting concerns.32

Our study has several limitations. Most significantly, multiple assumptions were made to reach an estimate of “stroke preventability”. In particular, the adequacy of hypertensive therapy was assessed on the last two prestroke readings, which may not be representative of longer-term trends.

As a hospital-based rather than population-based study, minor strokes may have been underrepresented, as well as strokes in nursing home patients. And as our study was set in a tertiary hospital stroke unit, neurosurgical and country referral patterns will have skewed the data. Subarachnoid haemorrhage was not included. Lastly, one investigator collected all the data and assessed the adequacy or otherwise of therapy, raising the possibility of bias.

In summary, in an Australian stroke unit-based cohort of consecutively admitted patients, many strokes were potentially preventable with optimal risk factor management, particularly in younger patients. This population was already being treated with one or more preventive therapies. This may account for the lesser extent of potential stroke reduction predicted by other studies. Nonetheless, tackling the major contributors — smoking, inadequate anticoagulation and hypertension (especially in patients with recommended systolic blood pressure targets of 130 mmHg or less) — would prevent a significant proportion of stroke. Far fewer patients will benefit from optimising thrombolysis.

1 Relative risk reductions from published studies for modification of designated risk factors for stroke

Risk factor that was modified

Relative risk reduction (95% CI)


Untreated hypertension9

30% (26%–32%)

Undertreated hypertension9

30%*

Grossly undertreated hypertension9

50%*

Untreated high-risk atrial fibrillation10

64% (49%–74%)

Aspirin-treated high-risk atrial fibrillation10

39% (22%–52%)

Untreated low- to medium-risk atrial fibrillation10

22% (6%–35%)

Smoking16

66% (50%–75%)

Untreated hypercholesterolaemia11

17% (12%–22%)

Untreated antiplatelet indication12

25% (22%–28%)

Untreated “normal” blood pressure after stroke14

28% (17%–38%)

Untreated symptomatic carotid disease15

61% (49%–72%)

Inappropriate hormone replacement therapy13

22% (12%–32%)

Subtherapeutic warfarinisation17

82%*


* 95% confidence intervals were not provided in the articles cited.

2 Demographic characteristics, prestroke risk factors and therapies, and stroke characteristics and outcomes for 259 patients admitted to Royal Adelaide Hospital stroke unit from 24 January 2006 to 10 January 2007

Variables

Findings


Demographic characteristics

Median age (years)

75 (IQR, 61–81)

Non-English-speaking background

73 (28%)

Female

114 (44%)

Lives alone

77 (30%)

Lives outside Adelaide

71 (27%)

Identifiable treating doctor

255 (98%)

Prestroke risk factors and therapies

Hypertension

161 (62%)

Current smoker

45 (17%)

Diabetes

46 (18%)

Atrial fibrillation

53 (20%)

Ischaemic heart disease

42 (16%)

Previous stroke

61 (24%)

Hypercholesterolaemia

77 (30%)

Any preventive therapy

181 (70%)

Antihypertensive therapy

157 (61%)

Warfarin therapy

28 (11%)

Antiplatelet therapy

111 (43%)

Statin therapy

73 (28%)

Stroke characteristics and outcome

Intracerebral haemorrhage

37 (14%)

Median admission National Institutes of Health stroke scale score

8 (IQR, 4–17)

Fatal stroke

41 (16%)

Median discharge modified Rankin scale

3 (IQR, 2–5)

Disabling stroke (modified Rankin scale, ≥ 4)

123 (47%)


IQR = interquartile range.

3 Total strokes preventable by optimal management of each risk factor for 135 patients with one or more risk factors

Risk factor

Total patients*

Relative risk reduction

Strokes preventable


Smoking

45

66%

26.4

Untreated hypertension

9

30%

2.4

Undertreated hypertension

31

30%

8.3

Grossly undertreated hypertension

26

50%

11.5

Total hypertension-related

22.2

Untreated high-risk atrial fibrillation

3

64%

1.7

Aspirin treated high-risk atrial fibrillation

18

39%

6.2

Untreated low-risk to medium risk atrial fibrillation

0

22%

0

Subtherapeutic warfarinisation

7

82%

5.1

Total atrial fibrillation-related

13.0

Untreated statin indication

6

17%

0.9

Untreated antiplatelet indication

18

25%

4.0

Untreated blood pressure after stroke

11

28%

2.7

Untreated symptomatic carotid

2

61%

1.1

Inappropriate hormone replacement therapy

0

22%

0

Total other

8.7


Strokes preventable (of 259)

70.3


* Some patients had more than one risk factor.
The percentage contribution of each factor to stroke preventability was adjusted if other risk factors were present and, in these patients, was less than the stated relative risk reduction.

4 Association of prospectively hypothesised demographic variables with relative risk of potentially preventable stroke

Demographic variable

Relative risk of preventable stroke (95% CI)

P


Age group (years)

< 60: ≥ 80

3.10 (1.96–4.92)

< 0.0001

60–69: ≥ 80

2.29 (1.23–4.23)

0.006

70–79: ≥ 80

1.13 (0.84–1.51)

0.43

Rural address (yes: no)

1.28 (1.01–1.62)

0.051

Non-English-speaking background (yes: no)

1.00 (0.77–1.29)

0.99

Lives alone (yes: no)

1.14 (0.90–1.46)

0.29

Male (yes: no)

1.01 (0.80–1.28)

0.92

5 Potential prevention of disability from stroke with optimal thrombolysis


RAH = Royal Adelaide Hospital.
tPA = tissue plasminogen activator.

  • Timothy J Kleinig1
  • Thomas E Kimber1
  • Philip D Thompson1,2

  • 1 Royal Adelaide Hospital, Adelaide, SA.
  • 2 University of Adelaide, Adelaide, SA.


Competing interests:

Timothy Kleinig received funding from Servier (manufacturer of perindopril) to attend the Australasian stroke conference in Perth in 2007.

  • 1. Sturm JW, Dewey HM, Donnan GA, et al. Handicap after stroke: how does it relate to disability, perception of recovery, and stroke subtype? The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002; 33: 762-768.
  • 2. Thrift AG, Dewey HM, Macdonell RA, et al. Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000; 31: 2087-2092.
  • 3. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000; 172: 592-596. <MJA full text>
  • 4. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke 2006; 37: 2181-2188.
  • 5. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
  • 6. Cadilhac D, Hankey G, Harris D, et al on behalf of the National Stroke Foundation and the National Stroke Audit Collaborative. National stroke audit clinical report acute services. Melbourne: NSF, 2007. http://www.strokefoundation.com.au/images/stories/healthprofession als/national%20stroke%20audit%20clinical %20report%20acute%20services.pdf (accessed May 2009).
  • 7. Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36: 483-488.
  • 8. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007; 38: 1881-1885.
  • 9. Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003; 21: 651-663.
  • 10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
  • 11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
  • 12. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
  • 13. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006; 113: 5-14.
  • 14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
  • 15. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107-116.
  • 16. Hankey GJ. Smoking and risk of stroke. J Cardiovasc Risk 1999; 6: 207-211.
  • 17. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004; 126: 1938-1945.
  • 18. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
  • 19. National Heart Foundation of Australia. Hypertension management guide for doctors. Canberra: NHFA, 2003.
  • 20. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 776-785.
  • 21. Hankey GJ, on behalf of the National Blood Pressure Advisory Committee of the National Heart Foundation. Non-valvular atrial fibrillation and stroke prevention [position statement]. Med J Aust 2001; 174: 234-239. <MJA full text>
  • 22. Baker RI, Coughlin PB, Gallus AS, et al; the Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497. <MJA full text>
  • 23. Hardie K, Jamrozik K, Hankey GJ, et al. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc Dis 2005; 19: 179-185.
  • 24. Curioni C, André C, Veras R. Weight reduction for primary prevention of stroke in adults with overweight or obesity. Cochrane Database Syst Rev 2006; (4): CD006062.
  • 25. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke 2003; 34: 2475-2481.
  • 26. Reynolds K, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289: 579-588.
  • 27. Marti-Fabregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1121.
  • 28. Chitravas N, Dewey HM, Nicol MB, et al. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007; 68: 1687-1693.
  • 29. Sturm JW, Davis SM, O’Sullivan JG, et al. The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust 2002; 176: 312-316. <MJA full text>
  • 30. Rother J, Alberts MJ, Touze E, et al. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25: 366-374.
  • 31. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21: 1583-1594.
  • 32. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.